Estónsko -
estónčina -
Ravimiamet
caspofungin sandoz infusioonilahuse kontsentraadi pulber
sandoz pharmaceuticals d.d. - kaspofungiin - infusioonilahuse kontsentraadi pulber - 50mg 1tk
Estónsko -
estónčina -
Ravimiamet
caspofungin xellia infusioonilahuse kontsentraadi pulber
xellia pharmaceuticals aps - kaspofungiin - infusioonilahuse kontsentraadi pulber - 70mg 1tk
Európska únia -
estónčina -
EMA (European Medicines Agency)
sarclisa
sanofi winthrop industrie - isatuximab - mitu müeloomit - antineoplastilised ained - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
Európska únia -
estónčina -
EMA (European Medicines Agency)
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastilised ained - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.